Geron Corporation (Nasdaq:GERN) today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer. GRN1005 is the company's lead LRP-directed peptide-drug conjugate (LRP-directed PDC) that consists of the cytotoxic drug, paclitaxel, linked to a peptide (Angiopep-2) that targets the LRP receptor to cross the blood-brain barrier (BBB) and to target tumors in the brain.
"There is a need for effective drugs for patients with cancer metastases in the brain," said Stephen M. Kelsey, M.D., Geron's Executive Vice President, Head of R&D and Chief Medical Officer. "We have been encouraged by the preliminary evidence of anti-tumor activity against brain metastases observed in the Phase 1 clinical trial of GRN1005, and we hope to confirm these results in the GRABM-B Phase 2 study in patients with brain metastases from breast cancer."
Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers